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Angiogenesis linked to  
activation of the innate immune 
response via Toll-like receptor 2 
during inflammation
West et al., Nature 2010; 467: 972–976; doi:10.1038/nature09421
Angiogenesis can either promote host defense and tissue repair 
or exacerbate organ dysfunction, resulting in disease. In many 
diseases, including in the kidney, altered angiogenesis and 
inflammation are related. Inflammatory cells release proang-
iogenic growth factors, including vascular endothelial growth 
factor, which facilitate neovascularization. Newly formed blood 
vessels enhance inflammatory-cell recruitment, thereby promot-
ing chronic inflammation. The mechanism of hypoxia-driven 
angiogenesis is well understood. However, the link between 
inflammation and de novo blood vessel growth remains obscure. 
West et al. link lipid oxidation products generated during tissue 
injury to Toll-like receptor 2 (TLR2) activation and neo-angio-
genesis. They show that end products of lipid oxidation, w-(2-
carboxyethyl)pyrrole and other related pyrroles, are generated 
during inflammation and wound healing and accumulate at high 
levels in ageing tissues in mice and in highly vascularized tumors. 
The molecular patterns of carboxyalkylpyrroles are recognized 
as danger signals by TLR2 on endothelial cells. The activation 
of TLR2 leads to an angiogenic response that is independent of 
vascular endothelial growth factor. Neutralization of endogenous 
carboxyalkylpyrroles impaired wound healing and tissue revas-
cularization and diminished tumor angiogenesis. Taken together, 
these findings establish a new function of TLR2 as a sensor of 
oxidation-associated molecular patterns, providing a key link 
connecting inflammation, oxidative stress, innate immunity, and 
angiogenesis. These findings may also apply to renal diseases such 
as diabetic nephropathy and extend the role of danger signals and 
TLR activation from inflammatory infiltrates during tissue injury 
to the resulting neo-angiogenesis.
Detlef Schlöndorff
Mechanism of protection  
by angiotensin II type 2  
receptor activation
Habashi et al., Science 2011; 332: 361–365; doi:10.1126/science.1192152
Angiotensin II interacts with two receptors, AT1 and AT2, which 
belong to the seven-transmembrane receptor superfamily. Much 
is known about the roles of AT1 in cardiovascular function and 
diseases, but data on the role of AT2 are sparse and less clear-cut. 
Initial pharmacological studies suggested that AT2 antagonizes 
AT1 signaling, but studies with AT2 transgenics and knockout 
mice have suggested more complex interactions. Nonetheless, it 
is established that in some cells and tissues, AT2 activation can 
oppose AT1-mediated enhancement of transforming growth 
factor-b (TGF-b) signaling. In addition, AT2 activation has the 
capacity to attenuate both canonical (Smad-dependent) and 
non-canonical (mitogen-activated protein kinase (MAPK)) 
TGF-b signaling cascades, most notably the extracellular signal–
regulated kinase (ERK). In a recent study, Habashi et al. exam-
ined the role of AT2 in a model of cardiovascular disease that 
is the murine equivalent of Marfan’s syndrome. The mice are 
heterozygous for a cysteine substitution in an epidermal growth 
factor–like domain of fibrillin-1 (Fbn1C1039G+/–), the most com-
mon class of mutation in people with Marfan’s. In these mice, 
TGF-b signaling is elevated and losartan treatment is protec-
tive. To examine the contribution of AT2, Habashi et al. bred 
the Fbn1C1039G+/– mice with mice with a disrupted Agtr2 allele 
(encoding AT2; AT2KO). They found that when compared 
with Fbn1C1039G+/– or AT2KO mice, AT2KO:Fbn1C1039G/+ mice 
had medial thickening, reduced elastin content, and increased 
elastic fiber fragmentation (Figure). Thus, loss of AT2 expres-
sion accelerated the aberrant growth and rupture of the aorta 
in this mouse model of Marfan’s syndrome. They also found 
that while the selective AT1 receptor blocker losartan abrogated 
aneurysm progression, full protection required intact AT2 sig-
naling. Indeed, the angiotensin-converting enzyme inhibitor 
enalapril, which limits signaling through both receptors, was 
much less effective. Interestingly, both losartan and enalapril 
attenuated canonical TGF-b signaling (Smad-dependent) in 
the aorta, but only losartan, by allowing continued signaling 
through AT2, inhibited TGF-b-mediated activation of ERK. This 
study greatly advances our understanding of the mechanisms 
whereby AT2 signaling might protect from angiotensin II effects 
that are mediated by TGF-b.
Juan Oliver
Aortas of wild-type (WT), AT2KO, Fbn1C1039G+/– (Marfan’s), and 
AT2KO:Fbn1C1039G/+ mice. Staining reveals diffuse fragmentation of 
elastic fibers and thickening of the media in Fbn1C1039G+/– mice; these 
findings are exaggerated in AT2KO:Fbn1C1039G/+ mice.
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Identification of new 
susceptibility loci for IgA 
nephropathy
Gharavi et al., Nat Genet 2011; 43: 321–327; doi:10.1038/ng.787
IgA nephropathy is the most common form of glomerulonephri-
tis. Diagnosis requires kidney biopsy showing notable prolifera-
tion of the glomerular mesangium with deposition of immune 
complexes composed of immunoglobulin A and complement 
C3 proteins. Registry data as well as autopsy and kidney-donor 
biopsy series have shown wide variation in its prevalence 
among populations with different ancestries; it is most fre-
quent among Asians (in whom it is the most common cause 
of renal failure), rare among people of African ancestry, and of 
intermediate prevalence among Europeans. The pathogenesis 
of IgA nephropathy is not fully defined, but IgA1 glycosylation 
abnormalities have been found among European, Asian, and 
African-American subjects with the disease, suggesting a shared 
pathogenesis among different groups. A genetic component to 
IgA nephropathy also appears likely, as familial aggregation of 
the disease has been reported. Previous linkage studies identified 
several loci predisposing individuals to IgA nephropathy, but the 
underlying genes are not known, and a single and unreplicated 
genome-wide association study (GWAS) in a small European 
cohort (533 cases) reported association of IgA nephropathy 
with the major histocompatibility complex. In a recent publi-
cation, Gharavi et al. report a GWAS for IgA nephropathy in a 
cohort of 3144 IgA nephropathy patients of Chinese and Euro-
pean ancestry. They studied 1194 patients and 902 controls of 
Chinese Han ancestry, with targeted follow-up in Chinese and 
European cohorts comprising 1950 patients and 1920 controls. 
They identified three independent loci in the major histocom-
patibility complex, as well as a common deletion of CFHR1 and 
CFHR3 at chromosome 1q32 (CFH encodes complement factor 
H) and a locus at chromosome 22q12 (a large interval encoding 
cytokines) that each surpassed genome-wide significance. These 
five loci explained up to a tenfold variation in interindividual 
risk and cumulatively accounted for 4–7% of the disease vari-
ance. The effect sizes at these loci were relatively large (compara-
ble to those previously detected in autoimmune or inflammatory 
diseases) and were consistent across the European and Chinese 
cohorts. The risk allele frequencies also strongly paralleled the 
prevalence of IgA nephropathy among the different popula-
tions. Interestingly, many of the alleles that protect against IgA 
nephropathy impart increased risk for other autoimmune or 
infectious diseases, and IgA nephropathy risk allele frequen-
cies closely paralleled the variation in disease prevalence among 
Asian, European, and African populations, suggesting complex 
selective pressures. Needless to say, the loci identified in this 
important study clarify the genetics of sporadic IgA nephropa-
thy and, importantly, identify new pathogenic pathways.
Juan Oliver
Use of angiotensin  
receptor blockers and  
the risk of cancer
Pasternak et al., Circulation 2011; 123: 1729–1736; doi:10.1161/
CIRCULATIONAHA.110.007336
A prior meta-analysis of randomized trials suggested the pos-
sibility that angiotensin receptor blockers (ARBs) caused an 
increased risk of malignancy focused on lung cancer.1 Paster-
nak et al. undertook to confirm this potential risk in an obser-
vational cohort. The investigators used the Civil Registration 
System, which included all people living in Denmark who 
were more than 35 years of age between 1 January 1998 and 
31 December 2006. Records were linked to pharmacy records 
to identify use of ARBs and angiotensin-converting enzyme 
(ACE) inhibitors, as well as to the Danish Cancer Registry to 
identify incident cancers. From a total population of more than 
3.3 million individuals, the final study cohort was 425,285 peo-
ple (107,000 receiving ARBs and 209,000 receiving ACE inhibi-
tors). The mean duration of use was 2.9 years (s.d. 2.2 years) 
and 2.1 years (s.d. 1.9 years) for ARBs and ACE inhibitors, 
respectively. ARBs were not associated with an increased risk 
of incident cancer. In univariate models, the rate ratio (RR) was 
0.89 (95% confidence interval (CI) 0.85–0.92). After adjustment 
for other medications as well as demographics, the RR was 0.99 
(95% CI 0.95–1.03). Further supporting the lack of a relation-
ship, the non-significant association did not change on the 
basis of length of ARB usage. People using ARBs for less than 
a year had a point estimate similar to that of those using ARBs 
for more than 5 years. When examined on the basis of cancer 
type, ARB use was associated with a modest but increased risk 
of male genital cancer (RR 1.15, 95% CI 1.02–1.28). The RR 
for all other cancers was 0.78 (95% CI 0.65–0.94). New safety 
concerns should always be approached with caution. One must 
find a careful balance between protecting at-risk people from 
any newly suggested increased risk and seeking to maintain 
the benefit of the agent. The risk of cancer associated with 
ARBs should be considered in this light. Prior findings dem-
onstrated consistent results with respect to prostate and lung 
cancer risk.1
While this current study does not confirm the risk in rela-
tion to lung cancer, it does not refute the relationship in rela-
tion to prostate cancer. Further, the observational nature of 
this study, with its inherent indication bias, is a limitation not 
seen in the meta-analysis.1 The nature of this risk requires 
continued exploration for a potential mechanism. Until one 
is found, this risk should be considered potential, and deci-
sions regarding need for an ARB as compared with an ACE 
inhibitor should be made on a case-by-case basis using the 
sum total of risk and benefit for the individual.
Lynda Szczech
1Lancet Oncol 2010; 11: 627–636.
